Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic neuropathic pain (pain persistent for greater than 6 months) that is moderate to severe in the opinion of the investigator~* Currently taking neuropathic pain medication limited to maximal allowed doses according to guidelines provided, but are not adequately controlled by standard of care~* Currently not taking neuropathic pain medications because they are intolerable to, or not willing to use, standard of care~* Mean average pain intensity score of at least 5, but less than 10, over 7 consecutive days on an 11-point numerical rating scale~* Pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus~* Required to have stable glycemic control~Exclusion Criteria:~* Patients with severe diabetic neuropathy defined by severe autonomic dysfunction or blood pressure instability Separate pain condition (e.g., joint osteoarthritis) that is more severe than their pain due to their diagnosis of Diabetic Peripheral Neuropathy~* Patients with evidence of another neuropathic pain not under the study, such as pain resulting from post-traumatic neuralgia, post-surgical neuropathy, complex regional pain, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, Human Immunodeficiency Virus (HIV) infection~* Major surgeries, trauma, and non-healing wounds/ulcers within 3 months prior to study medication~* History of severe traumatic brain injury within the past 15 years~* Other peripheral neuropathy, parasthesia or dyesthesia or previously diagnosed neurological condition causing these symptoms not related with diabetic painful neuropathy under study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-42160443 (1 mg) (Type: EXPERIMENTAL): JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
- JNJ-42160443 (3 mg) (Type: EXPERIMENTAL): JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
- JNJ-42160443 (10 mg) (Type: EXPERIMENTAL): JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval